

LAGOSTA to supply chitosan for biomedical industry through the Life Science business of Merck

Saint-Prex, Switzerland, October 23, 2023—LAGOSTA S.A. announces that it has entered into a collaboration with the global science and technology company Merck for the distribution of LAGOSTA's unique chitosan through their Life Science business' industry-leading eCommerce platform. The compound can be used by pharma, biotech and the biomedical industry for R&D use only, in drug delivery applications, 3D bioprinting and medical devices.

Under the agreement, the Life Science business of Merck will employ its sales, marketing and eCommerce expertise, and leverage the strength of its relationships with the scientific community, to present and distribute LAGOSTA's premium chitosan. For more information go to [www.sigma-aldrich.com](http://www.sigma-aldrich.com)

“This partnership clearly underlines and validates the uniqueness of our outstanding chitosan profile. Accessing such a premium product via Merck unlocks an unlimited potential of biomedical development opportunities for scientists around the world” said Christophe Maier, Founder and CEO at LAGOSTA S.A.

Through a farmed, sustainable production, LAGOSTA allows for high quality and consistent reproducibility chitosan, a biopolymer which we know is antimicrobial, biocompatible and biodegradable, unlocking potential for research in a number of areas, from implants to batteries.

#### **About Merck**

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck generated sales of € 22.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to [www.merckgroup.com/subscribe](http://www.merckgroup.com/subscribe) to register online, change your selection or discontinue this service.

#### **About LAGOSTA**

LAGOSTA is a Swiss blue biotech company, expert in biomedical chitosan production.

This new generation chitosan product, the first of its kind on the market, is derived from the spiny lobster by-products, is traceable, exhibits high levels of purity and most importantly, is reproducible.

For more information about the company, please, visit [www.lagosta.com](http://www.lagosta.com)